↓ Skip to main content

Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review

Overview of attention for article published in Annals of Hematology, January 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#48 of 1,108)
  • Good Attention Score compared to outputs of the same age (74th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news
1 news outlet

Citations

dimensions_citation
39 Dimensions

Readers on

mendeley
91 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review
Published in
Annals of Hematology, January 2016
DOI 10.1007/s00277-015-2585-7
Pubmed ID
Authors

Scott C. Howard, Steven Trifilio, Tara K. Gregory, Nadine Baxter, Ali McBride

Abstract

Effective new treatments are now available for patients with hematologic malignancies. However, their propensity to cause tumor lysis syndrome (TLS) has not been systematically examined. A literature search identified published Phase I-III clinical trials of monoclonal antibodies (otlertuzumab, brentuximab, obinutuzumab, ibritumomab, ofatumumab); tyrosine kinase inhibitors (alvocidib [flavopiridol], dinaciclib, ibrutinib, nilotinib, dasatinib, idelalisib, venetoclax [ABT-199]); proteasome inhibitors (oprozomib, carfilzomib); chimeric antigen receptor (CAR) T cells; and the proapoptotic agent lenalidomide. Abstracts from major congresses were also reviewed. Idelalisib and ofatumumab had no reported TLS. TLS incidence was ≤5 % with brentuximab vedotin (for anaplastic large-cell lymphoma), carfilzomib and lenalidomide (for multiple myeloma), dasatinib (for acute lymphoblastic leukemia), and oprozomib (for various hematologic malignancies). TLS incidences were 8.3 and 8.9 % in two trials of venetoclax (for chronic lymphocytic leukemia [CLL]) and 10 % in trials of CAR T cells (for B-cell malignancies) and obinutuzumab (for non-Hodgkin lymphoma). TLS rates of 15 % with dinaciclib and 42 and 53 % with alvocidib (with sequential cytarabine and mitoxantrone) were seen in trials of acute leukemias. TLS mitigation was employed routinely in clinical trials of alvocidib and lenalidomide. However, TLS mitigation strategies were not mentioned or stated only in general terms for many studies of other agents. The risk of TLS persists in the current era of novel and targeted therapy for hematologic malignancies and was seen to some extent with most agents. Our findings underscore the importance of continued awareness, risk assessment, and prevention to reduce this serious potential complication of effective anticancer therapy.

Mendeley readers

The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Peru 1 1%
Mexico 1 1%
Japan 1 1%
United States 1 1%
Unknown 87 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 19 21%
Unspecified 16 18%
Other 11 12%
Student > Postgraduate 9 10%
Student > Ph. D. Student 8 9%
Other 28 31%
Readers by discipline Count As %
Medicine and Dentistry 38 42%
Unspecified 20 22%
Agricultural and Biological Sciences 11 12%
Pharmacology, Toxicology and Pharmaceutical Science 7 8%
Biochemistry, Genetics and Molecular Biology 7 8%
Other 8 9%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 June 2018.
All research outputs
#2,091,013
of 13,099,076 outputs
Outputs from Annals of Hematology
#48
of 1,108 outputs
Outputs of similar age
#66,400
of 270,321 outputs
Outputs of similar age from Annals of Hematology
#3
of 36 outputs
Altmetric has tracked 13,099,076 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,108 research outputs from this source. They receive a mean Attention Score of 2.4. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 270,321 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.